Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease
- Conditions
- UstekinumabVitamin D SupplementationCrohn's DiseaseClinical Efficacy
- Registration Number
- NCT05867784
- Lead Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Brief Summary
It is uncertain whether vitD3 supplementation is beneficial for the remission of Crohn's disease (CD). The effects of vitD3 supplements on the efficacy of ustekinumab in Chinese CD patients were retrospectively analyzed. Methods: Patients with moderate to severe CD were recorded. These patients were initially treated with UST. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of UST and continued throughout the follow-up period. Disease activity was assessed using Harvey Bradshaw Index.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
- moderate-to-severe CD
- Treated with Ustekinumab
- had recent supplementation of vitD3
- pregnant
- had cognitive/developmental disorders that affected their ability to complete the study procedures
- had medical illness or therapies potentially affecting bone, nutrition or growth status
- unknown or untested baseline serum 25(OH)D level
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum 25 (OH) D level 24 weeks Vitamin D deficiency is defined as serum 25 (OH) D level\<20 μ g/L
disease activity 24weeks Harvey Bradshaw Index,mild: 0 to 8, moderate: 9 to 16, severe: 17 to 25
- Secondary Outcome Measures
Name Time Method Serum 25 (OH) D level 8 weeks Vitamin D deficiency is defined as serum 25 (OH) D level\<20 μ g/L
Trial Locations
- Locations (1)
SAHWenzhouMU
🇨🇳Wenzhou, Zhejiang, China